While other genetic events have been described to dysregulate the p53 pathway in GIST, such as deletions of p16 or amplification of MDM2, these would not preclude the use of MDM2 inhibitors but could rather sensitize cells to a treatment [20], [21]. The gene discussed is CDKN2A; the disease is gastrointestinal stromal tumor.